William Blair, Sofi and Affirm
Research analysts at William Blair issued their Q2 2025 EPS estimates for shares of Affirm in a research report issued to ...
William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...
Stock Trading Recap. On Friday, Tenaya Therapeutics Inc (TNYA) stock saw a modest uptick, ending the day at $1.4 which represents a slight increase ...
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...
Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...
William Blair International Growth Fund earns an Average Process Pillar rating. The most important driver of the rating is the stability of the management team. Specifically, the fund has not seen ...
For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...
William Blair analyst Andrew Jeffrey initiated coverage of SoFi Technologies (SOFI) with an Outperform rating and no price target The firm ...
"It is my pleasure to welcome Terence to William Blair’s Healthcare investment banking practice and its biopharma group," said Steve Tole, head of Healthcare investment banking at William Blair. "Our ...
Portillo’s has never been one to follow the worn path in quick service. It hasn’t engaged in the “value wars” or materially ...
Equities research analysts at William Blair cut their Q4 2025 earnings per share estimates for shares of Karooooo in a report ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback